Shares of InVitae Corp (NYSE:NVTA) have received a consensus rating of “Hold” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $14.33.

Several equities analysts have recently commented on the stock. BidaskClub cut shares of InVitae from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 15th. Leerink Swann reduced their price target on shares of InVitae from $14.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 7th. Finally, Zacks Investment Research cut shares of InVitae from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th.

Several hedge funds have recently modified their holdings of NVTA. TIAA CREF Investment Management LLC lifted its position in shares of InVitae by 32.8% during the first quarter. TIAA CREF Investment Management LLC now owns 121,549 shares of the medical research company’s stock worth $1,344,000 after purchasing an additional 30,039 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of InVitae by 9.8% during the first quarter. Vanguard Group Inc. now owns 1,206,266 shares of the medical research company’s stock worth $13,341,000 after purchasing an additional 107,775 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of InVitae by 9.3% during the first quarter. Geode Capital Management LLC now owns 249,737 shares of the medical research company’s stock worth $2,761,000 after purchasing an additional 21,267 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of InVitae by 73.6% during the first quarter. Renaissance Technologies LLC now owns 192,200 shares of the medical research company’s stock worth $2,126,000 after purchasing an additional 81,500 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of InVitae by 27.0% during the first quarter. Schwab Charles Investment Management Inc. now owns 104,994 shares of the medical research company’s stock worth $1,162,000 after purchasing an additional 22,301 shares during the last quarter. 66.52% of the stock is currently owned by institutional investors and hedge funds.

InVitae (NVTA) traded down $0.19 during trading hours on Monday, reaching $8.45. 195,053 shares of the company’s stock were exchanged, compared to its average volume of 134,091. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.61 and a quick ratio of 2.61. InVitae has a one year low of $2.60 and a one year high of $8.95.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/11/invitae-corp-nvta-receives-consensus-rating-of-hold-from-brokerages.html.

InVitae Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.